Riskpilot← Back to searchSign inGet full accessSB1 Pharma AB
ABBankruptOrg 5592009954Research and experimental development on natural sciences and engineering · NACE 7210Est. 20190 employees
Revenue 2023
SEK 0
EBITDA margin
—
+89% vs 2022
Equity ratio
-16.0%
Financial strength
Net profit 2023
SEK -91K
+46% vs 2022
| Revenue | SEK 0 | — |
| EBITDA | SEK -7K | +89% |
| Net profit | SEK -91K | +46% |
| Total assets | SEK 536K | -11% |
| Equity | SEK -86K | -69% |
| Employees | 0 | — |
Legal name
SB1 Pharma AB
Org number
5592009954
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
2 april 2019
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Styrelsen ska bestå av 2 styrelseledamöter och 1 styrelsesuppleant.
Company purpose
Bolaget skall bedriva forskning, utveckling och kommersialisering av cancerdiagnostik samt handel och förvaltning av värdepapper och därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −36 | −69 | −60 | −66 | −7 |
| Depreciation & amort. | −13 | −75 | −75 | −75 | −77 |
| EBIT | −49 | −144 | −135 | −141 | −84 |
| Net financials | — | −6 | −22 | −28 | −8 |
| Profit before tax | −49 | −150 | −156 | −169 | −91 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −49 | −150 | −156 | −169 | −91 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 792 | 1 046 | 847 | 600 | 536 |
| Equity | 393 | 256 | 116 | −51 | −86 |
| Long-term debt | 0 | 333 | 220 | 203 | 173 |
| Short-term debt | 399 | 456 | 511 | 448 | 449 |
| Total debt | 399 | 789 | 731 | 651 | 622 |
EBITDA margin
-700000.0%
This company
15.8%
Market median
-4430480% vs market
20192023
Equity ratio
-16.0%
This company
38.2%
Market median
-142% vs market
20192023
Return on equity
-9100000.0%
This company
18.4%
Market median
-49456622% vs market
20192023
Net profit margin
-9100000.0%
This company
8.1%
Market median
-112345779% vs market
20192023
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20192023
Debt / equity
7.23×
This company
0.62×
Market median
-1066% vs market
20192023
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-04-01 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PÅ Chief Auditor | Chief Auditor | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of SB1 Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Åke Joakim Stomberg | Chief Auditor | 0 companies |
| Karin Marie Christine Widstrand | Board of Directors | 0 companies |
| Johan Reinhold Martin Oskarsson | Deputy Board Member | 0 companies |
| Tomas Jörgen Eriksson | Chairman | 0 companies |
| Ulrike Anna Liselotte Nuber | Board of Directors | 0 companies |
| Karl Bengt Göran Svensson | Chairman | 0 companies |